AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
AbbVie(ABBV) ZACKS·2025-01-07 12:55
In an SEC filing, AbbVie (ABBV) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.Including ...